Shivani Sharma, Saroj Kumar, Manendra Singh Tomar, Divya Chauhan, Chirag Kulkarni, Swati Rajput, Sreyanko Sadhukhan, Konica Porwal, Rajdeep Guha, Ashutosh Shrivastava, Jiaur R Gayen, Navin Kumar, Naibedya Chattopadhyay
Chronic kidney disease-induced secondary hyperparathyroidism (CKD-SHPT) heightens fracture risk through impaired mineral homeostasis and elevated levels of uremic toxins (UTs), which in turn enhance bone remodeling. Etelcalcetide (Etel), a calcium-sensing receptor (CaSR) agonist, suppresses parathyroid hormone (PTH) in hyperparathyroidism to reduce excessive bone resorption, leading to increased bone mass. However, Etel's effect on bone quality, chemical composition, and strength is not well understood. To address these gaps, we established a CKD-SHPT rat model and administered Etel at a human-equivalent dose concurrently with disease induction...
May 20, 2024: Bone